Andrew Simon's Contact Details

Andrew Simon's Company Details

Ventria Bioscience is the first company to commercialize recombinant proteins derived from a plant-based manufacturing system. These products are being developed as human therapeutics and as bioreagents to improve biomanufacturing. Ventria's technology platform ExpressTec is a safe, affordable and sustainable manufacturing technology that achieves recombinant protein yield that is many times higher than alternative systems. This advantage means Ventria's products are accessible to a global customer base. For more information see www.Ventria.comInVitria is a Division of Ventria Bioscience that develops and markets products used globally to improve productivity, consistency and safety of biopharmaceuticals, cellular therapies, regenerative medicines, medical devices and diagnostics. See www.InVitria.com